HELP:NASDAQ
Cybin Inc
11,70 $
arrow_downward
-1,76%(-0,21) 1 d.
11,70 $
0,00% (0,00)
bedtimePēctirdzniecības
Slēgts: 2. okt., 16:00:01 GMT-4 · USD
search
Visi simboli
| Simbols | Cena | Izmaiņas | % izmaiņu |
|---|
insights_autoNotiek galveno ieskatu ģenerēšana par šādu tēmu: HELP…
Atvērt
12,30 $
Augsta
12,30 $
Zema
11,52 $
Vid. apjoms
1,73 milj.
Apjoms
1,41 milj.
Augstākā 52 ned.
15,15 $
Zemākā 52 ned.
3,76 $
Apgrozībā esošās akcijas
73,06 milj.
Darbinieku skaits
100
Atvērt
12,30 $
Augsta
12,30 $
Zema
11,52 $
Vid. apjoms
1,73 milj.
Apjoms
1,41 milj.
Augstākā 52 ned.
15,15 $
Zemākā 52 ned.
3,76 $
Apgrozībā esošās akcijas
73,06 milj.
Darbinieku skaits
100
Ziņas un raksti
No tīmekļa avotiem un ziņu partneriem
TipRanks
·
pirms 2 dienām
Helus Pharma Finalizes Legal Name Change as It Prepares for Commercial Push
Helus Pharma
·
pirms 3 dienām
Helus Pharma Announces Completion of Legal Name Change - Thu, 10/01/2026 - 07:30
Profils
Helus Pharma, also known formerly as Cybin IRL, is a Canadian pharmaceutical company that was led by CEO Doug Drysdale from 2020-2025, developing psychedelic drugs as medicines.
The company's drug candidates include psilocybin, HLP002, deupsilocin, deudimethyltryptamine, HLP005, and HLP006. Another drug that the company has developed is CYB210010.
As of January 2025, deupsilocin is in phase 3 clinical trials. The drug is one of the only other psychedelics besides Compass Pathways's COMP360 to have reached this late stage of clinical development.
In 2020, Helus Pharma acquired psychedelic pharmaceutical company Adelia Therapeutics. In late 2023, it acquired Small Pharma, the developer of SPL026 and SPL028. Helus Pharma was originally known as Cybin but changed its name in December 2025. Wikipedia
Par “Cybin Inc”
Ģenerāldirektors-
Darbinieki100
Dibināšanas datums2019
Galvenais birojsToronto, Ontārio, Kanāda
Sektors-
Tīmekļa vietnehelus.com